Acquiring Company
ZYMEWORKS
Acquired Company
Theravance Biopharma
Vancouver
DublinBiotechnologyBiotechnologyHealth CareDescription
Zymeworks has successfully closed its acquisition of Theravance Biopharma, enhancing its commercial capabilities and revenue potential. This acquisition adds significant assets, including YUPELRI profit-sharing rights and royalties. Zymeworks expects this transaction to lead to continued growth in its revenue mix and collaboration efforts.
Fundz sees it the moment ZYMEWORKS makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Theravance Biopharma?
Theravance Biopharma was acquired by ZYMEWORKS, based in Vancouver. The deal was reported on October 4, 2026. Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. ZYMEWORKS is publicly traded (ZYME) and operates in Biotechnology.
When did ZYMEWORKS acquire Theravance Biopharma?
ZYMEWORKS's acquisition of Theravance Biopharma was reported on October 4, 2026. Zymeworks has successfully closed its acquisition of Theravance Biopharma, enhancing its commercial capabilities and revenue potential. This acquisition adds significant assets, including YUPELRI profit-sharing rights and royalties. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Theravance Biopharma do?
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. It is publicly traded (TBPH), operating in Biotechnology, and is based in Dublin.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.